

Brilliant Violet 421™ anti-mouse CD152

Catalog # / Size: 1131560 / 50 µg
1131555 / 125 µl

Clone: UC10-4B9

Isotype: Hamster IgG


Immunogen: Mouse CTLA-4-mouse IgG2a fusion protein

Reactivity: Mouse

Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions. The solution is free of unconjugated Brilliant Violet 421™ and unconjugated antibody.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Concentration: microg sizes: 0.2 mg/ml
microL sizes: lot-specific




Con A+IL-2-stimulated C57BL/6 splenocytes (3 days) were stained with CD3 APC and CD152 (clone UC10-4B9) Brilliant Violet 421™ (top) or Armenian Hamster IgG Brilliant Violet 421™ isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the microg size, the suggested use of this reagent is ≤1.0 microg per million cells in 100 microL volume. For immunofluorescent staining using the microL size, the suggested use of this reagent is ≤5 microL per million cells or 5 microL per 100 microL of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.



Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner

into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Application Notes: The UC10-4B9 antibody can enhance T cell co-stimulation by blocking CTLA-4 interactions with the B7 co-receptors, favoring CD28 interactions. Additional reported applications (for the relevant formats) include: immunoprecipitation¹, *in vitro* stimulation, *in vitro* and *in vivo* blocking¹⁻⁴ of ligand binding, and as ELISA capture antibody⁵. To reduce non-specific binding to cells bearing Fc-receptors, pre-incubation of cells with anti-mouse CD16/CD32, clone 93 (Cat. No. 101301/101302), is recommended prior to immunofluorescent staining. For most successful immunofluorescent staining results, it may be important to maximize signal over background by using a relatively bright fluorochrome-antibody conjugate (Cat. No. 106306) or by using a high sensitivity, three-layer staining technique (e.g., including a biotinylated anti-Armenian hamster IgG (Cat. No. 405501) second step, followed by SAv-PE (Cat. No. 405204)). The LEAF™ purified antibody (Endotoxin <0.1 EU/μg, Azide-Free, 0.2 μm filtered) is recommended for functional assays (Cat. No. 106308).

Application References:

1. Walunas TL, *et al.* 1994. *Immunity* 1:405. (Block, IP)
2. Cilio CM, *et al.* 1998. *J. Exp. Med.* 188:1239. (Block)
3. Issazadeh S, *et al.* 1999. *J. Immunol.* 162:761. (Block)
4. McCoy K, *et al.* 1997. *J. Exp. Med.* 186:183. (Block)
5. Hsu HC, *et al.* 2007. *J. Immunol.* 178:5357. (ELISA Capture)
6. Sugita S, *et al.* 2010. *Invest. Ophthalmol. Vis. Sci.* 51:5783. [PubMed](#)

Description: CD152, also known as CTLA-4 or Ly-56, is a 33 kD member of the immunoglobulin superfamily. It is expressed on activated T and B lymphocytes. CD152 is similar to CD28 in amino acid sequence, structure, and genomic organization and these two receptors share common B7 family counter-receptors (B7-1, B7-2). Whereas CD28 delivers a costimulatory signal in T cell activation, CTLA-4 negatively regulates cell-mediated immune responses. CD152 is thought to play a role in the induction and maintenance of immunological tolerance as well as the development of protective immunity and thymocyte regulation.

Antigen References:

1. Barclay A, *et al.* 1997. *The Leukocyte Antigen FactsBook* Academic Press.
2. Allison JP, *et al.* 1995. *Science* 270:932.
3. Waterhouse P, *et al.* 1995. *Science* 270:985.
4. Linsley PS, *et*